Westlake Village, California, United States – March 10, 2026
Arcutis Biotherapeutics has announced that the U.S. Food and Drug Administration (FDA) has approved ZORYVE® (roflumilast) cream 0.05% for the treatment of mild-to-moderate atopic dermatitis in children aged 2 to 5 years, marking a significant advancement in pediatric dermatology treatment. The once-daily, steroid-free topical therapy provides rapid relief of eczema symptoms while addressing the underlying inflammatory pathways associated with the disease, offering clinicians and families a new long-term treatment option for young children. The approval highlights Arcutis’ growing leadership in immuno-dermatology innovation, with ZORYVE becoming one of the most widely recognized topical therapies targeting inflammatory skin conditions.
Clinical Trials Demonstrate Rapid Improvement in Atopic Dermatitis
The FDA approval of ZORYVE cream 0.05% was supported by results from the Phase 3 INTEGUMENT-PED clinical trial, which evaluated the safety and efficacy of the treatment in 652 children between the ages of 2 and 5 years suffering from mild-to-moderate atopic dermatitis. The randomized, double-blind, vehicle-controlled study demonstrated significant improvements in disease severity, itch reduction, and overall skin clearance compared with placebo treatments.
Clinical trial data showed that 25.4% of children treated with ZORYVE achieved clear or almost clear skin after four weeks of treatment, compared with 10.7% of children receiving the control treatment, a statistically significant improvement in clinical outcomes. Additionally, 39.4% of participants treated with ZORYVE achieved a 75% improvement in the Eczema Area and Severity Index (EASI-75) within four weeks, nearly double the improvement seen in the control group.
Researchers also observed rapid relief of itching symptoms, one of the most disruptive aspects of atopic dermatitis. Some caregivers reported noticeable improvements in itching within 24 hours after the first application, helping break the persistent itch-scratch cycle that often worsens the disease in young children.
Advertisement
Long-Term Safety and Sustained Efficacy Confirmed
In addition to the pivotal clinical trial, long-term safety and efficacy data were collected through the INTEGUMENT-OLE extension study, which followed participants for up to 56 weeks of treatment. The findings demonstrated that ZORYVE maintained its therapeutic effectiveness over time while continuing to show a favorable safety profile, reinforcing its suitability for long-term disease management.
At the 56-week follow-up, 71.9% of participants who continued treatment achieved significant improvements in eczema severity, confirming the therapy’s sustained benefits for pediatric patients. Participants who achieved clear skin were able to switch to proactive twice-weekly maintenance therapy, maintaining disease control for a median duration of approximately 238 days.
Importantly, ZORYVE cream was well tolerated in clinical studies, with the most commonly reported adverse events including upper respiratory tract infections, diarrhea, vomiting, rhinitis, conjunctivitis, and headache. These events were generally mild and consistent with the expected safety profile for topical dermatological therapies.
Innovative Steroid-Free Treatment for Pediatric Eczema
Atopic dermatitis is the most common form of eczema, affecting millions of children worldwide and approximately 1.8 million children between the ages of 2 and 5 in the United States alone who require topical treatment. The condition is characterized by chronic inflammation, intense itching, redness, and skin barrier dysfunction, often leading to sleep disruption and reduced quality of life for both children and caregivers.
Traditional treatments for pediatric eczema frequently rely on topical corticosteroids, which can present challenges for long-term use due to potential side effects such as skin thinning and systemic absorption risks. ZORYVE offers a steroid-free alternative that targets phosphodiesterase-4 (PDE4), an enzyme responsible for promoting inflammatory responses in the skin.
By inhibiting PDE4 activity, ZORYVE reduces the production of pro-inflammatory mediators while increasing anti-inflammatory signals, helping restore normal skin function and reduce disease activity. Because the cream can be applied once daily and used on any area of the body for extended periods, it offers clinicians a flexible treatment option for managing chronic eczema in young patients.
The latest approval represents the sixth FDA authorization for the ZORYVE product portfolio in just over three years, reflecting the therapy’s expanding role in dermatology. Arcutis plans to make the treatment widely available through pharmacies and healthcare providers, ensuring that families and clinicians have access to a safe, effective, and long-term solution for pediatric eczema management.
As dermatological research continues to evolve, innovative topical therapies such as ZORYVE are expected to play an increasingly important role in improving quality of life for patients with chronic inflammatory skin diseases, particularly in pediatric populations where safe long-term treatment options remain limited.
z
Source: Arcutis Biotherapeutics press release
